Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.

What Was Tested

This clinical trial looks at Glucagon.

Hyperglycemia, in association with hyperinsulinemia, stimulates this metabolic change but may have deleterious effects on left ventricular (LV) function.

The incretin hormone, glucagon-like peptide-1 (GLP-1), also has favorable cardiovascular effects, and has emerged as an alternative method of altering myocardial substrate utilization.

Who Took Part

The study group was 1, patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In study 1, twelve patients underwent two DSEs with tissue Doppler imaging (TDI)-one during the steady-state phase of a HHC.

In study 2, ten patients with T2DM underwent two DSEs with TDI during the steady-state phase of a HHC.

How the Study Was Run

In both studies, global LV function was assessed by ejection fraction and mitral annular systolic velocity, and regional wall LV function was assessed using peak systolic velocity, strain and strain rate from 12 paired non-apical segments.

What Was Measured

The subject headings attached to it are Biomarkers, Biomechanical Phenomena, Blood Glucose, Coronary Artery Disease, Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies and Echocardiography, Doppler, Color.

What This Means in Plain Language

This is a clinical trial of Glucagon in 1, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Cardiovascular diabetology), a journal based in England.

More context: the Glucagon compound page, all human trials.